
Curanex Pharmaceuticals Inc Common Stock
CURXHealthcare|Biotechnology|US
$6.21
+0.43 (+7.44%)
DCF Value
$3.26
Tangible Book / Share
$3.38
Cash / Share
$2.07
About
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
Stock Price
-49.3%(1Y)
1M
+30.5%
3M
+59.2%
6M
-3.9%
YTD
-6.1%
1Y
-47.0%
3Y
-92.3%
5Y
-92.3%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$9.7M
Employees6
CEOJun Liu
IPO DateAug 26, 2025
Beta-2.57
52-Week Range$3.58 – $13.34
Avg Volume17,048
ExchangeNASDAQ
Websitecuranexpharma.com
Ownership
Float26.6%
Shares Outstanding1.6M
Recent Insider Trades
Xie LiqinOTHER
Aug 25, 20250 shares
Hsu Helen HongOTHER
Aug 25, 20250 shares
Zhong HuijuanOTHER
Aug 25, 20250 shares
Yan YongOTHER
Aug 25, 20250 shares
Liu JunOTHER
Aug 25, 20250 shares
Peers
Data last updated: Nov 9, 2026, 04:05 AM